The tRNA-derived fragment signature in lung cancer
Pradeep Reddy Cingaram
Molecular Therapy: Oncolytics · 2022
doi:10.1016/j.omto.2022.09.002 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
A new class of regulatory small non-coding RNAs called tRNA-derived fragments (tRDFs) has distinct biological roles in various types of cancer. In this issue of Molecular Therapy – Oncolytics, Zitong Gao et al. performed a thorough study of tRDFs in 1,550 patient samples of non-small cell lung cancer (NSCLC) and discovered 52 tRDFs with four subtypes. Based on expression profiles, six tRDFs were selected as diagnostic biomarkers. Two of these biomarkers were successfully validated in plasma samples, and six biomarkers confirmed the consistency of distinguished expression in NSCLC cell lines.
Abstract licence: CC BY-NC-ND
References5
5 more references, whose wording the paper’s licence keeps private.
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.